Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Talha Badar, MBBS,FCPS, Philip A Thompson, MBBS, Binsah George, MD, Naval Daver, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Zach Bohannan, Sherry Pierce, BSN, BA, Elias Jabbour, MD, Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Keyur P. Patel, MD PhD, Raja Luthra, Victoria Sukholutsky, Guillermo Garcia Manero, MD

Blood (2014) 124 (21): 4631.

https://doi.org/10.1182/blood.V124.21.4631.4631

Published: 2014

Journal Articles

Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)

Talha Badar, MBBS,FCPS, Hagop M. Kantarjian, MD, Farhad Ravandi, MD, Elias Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD, Naveen Pemmaraju, MD, Sherry R. Pierce, RN, BS, Naval Daver, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3186.

https://doi.org/10.1182/blood.V124.21.3186.3186

Published: 2014

Journal Articles

Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase

Binsah George, MD, Williams Lori, Quiling Shi, MD PhD, Talha Badar, MBBS,FCPS, Susan O'Brien, MD, Elias Jabbour, MD, Guillermo Garcia-Manero, MD, Nitin Jain, MD, Farhad Ravandi, MBBS, Gautam Borthakur, MD, William Wierda, MD PhD, Charles S. Cleeland, PhD, Hagop M. Kantarjian, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 4548.

https://doi.org/10.1182/blood.V124.21.4548.4548

Published: 2014

Journal Articles

Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia ( MLL ) Gene Rearrangements

Talha Badar, MBBS,FCPS, Hagop M. Kantarjian, MD, Susan O'Brien, Guillermo Garcia-Manero, MD, Elias Jabbour, MD, Rebecca Garris, BSc, Naveen Pemmaraju, MD, Naval Daver, MD, Farhad Ravandi, MD, Jorge Cortes, MD, Deborah A. Thomas, MD

Blood (2014) 124 (21): 5342.

https://doi.org/10.1182/blood.V124.21.5342.5342

Published: 2014

Journal Articles

Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade

Talha Badar, MBBS,FCPS, Hagop M. Kantarjian, MD, Gautam Borthakur, MD, Guillermo Garcia Manero, MD, Michael Andreeff, MD PhD, Marina Konopleva, MD PhD, Tapan M. Kadia, MD, Naval Daver, MD, William G. Wierda, MD PhD, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2014) 124 (21): 949.

https://doi.org/10.1182/blood.V124.21.949.949

Published: 2014

Journal Articles

Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years

Aditya Shetty, MD, Hagop M Kantarjian, MD, Richard E Champlin, MD, Gautam Borthakur, MD, Talha Badar, MBBS, FCPS (Medical Oncology), Guillermo Garcia-Manero, MD, Borje S. Andersson, MD, PhD, Betul Oran, MD, Stefan O. Ciurea, MD, Marina Konopleva, MD, PhD, Michael Andreeff, MD, PhD, Steven M. Kornblau, MD, William G. Wierda, MD, Sherry Pierce, Farhad Ravandi, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3886.

https://doi.org/10.1182/blood.V122.21.3886.3886

Published: 2013

Journal Articles

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Talha Badar, MBBS, FCPS, Gloria Mattiuzzi, MD, Hagop M Kantarjian, MD, Farhad Ravandi, MD, Naval G. Daver, MD, Guillermo Garcia Manero, MD, Tapan M. Kadia, MD, Elias J. Jabbour, MD, Gautam Borthakur, MD, Jorge E. Cortes, MD

Blood (2013) 122 (21): 3887.

https://doi.org/10.1182/blood.V122.21.3887.3887

Published: 2013

NARROW

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)

Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase

Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia ( MLL ) Gene Rearrangements

Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade

Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Email alerts

ASH Publications

American Society of Hematology

Temporal Acquisition of FLT3-ITD or RAS Mutation at Transformation to AML from MDS: Clinical Implications

Therapeutic Benefit of Decitabine, a Hypomethylating Agent, in Patients with Myeloproliferative Neoplasm in Blastic Phase/Acute Myeloid Leukemia (MPN-AML), Accelerated Phase (MPN-AP), and DIPSS-Plus High Risk Primary Myelofibrosis (PMF)

Retrospective Analysis to Correlate Impact of Symptom Burden and Quality of Life to Treatment Outcome with Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia Chronic Phase

Clinical Outcome of De Novo Adult Acute Lymphoblastic Leukemia (ALL) with 11q23/Mixed Lineage Leukemia ( MLL ) Gene Rearrangements

Improvement in Clinical Outcome of FLT3 Mutated AML Patients over the Last One and a Half Decade

Survivorship In AML - Outcomes Of Acute Myelogenous Leukemia (AML) Patients (pts) After Maintaining Complete Remission (CR) For At Least 3 Years

Phase II, Open Label, Randomized Comparative Trial Of Ondansetron Alone Versus The Combination Of Ondansetron Plus Aprepitant For The Prevention Of Nausea and Vomiting In Patients (Pts) With Hematological Malignancies Receiving Regimens Containing High Dose Cytarabine

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only